# A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

> **NCT02536183** · PHASE1 · TERMINATED · sponsor: **AeRang Kim** · enrollment: 2 (actual)

## Conditions studied

- Pediatric Cancer
- Solid Tumors
- Rhabdomyosarcoma
- Ewing Sarcoma
- Soft Tissue Sarcomas
- Osteosarcoma
- Neuroblastoma
- Wilms Tumor
- Hepatic Tumor
- Germ Cell Tumors

## Interventions

- **DEVICE:** Magnetic resonance high intensity focused ultrasound
- **DRUG:** Lyso-thermosensitive liposomal doxorubicin

## Key facts

- **NCT ID:** NCT02536183
- **Lead sponsor:** AeRang Kim
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10
- **Primary completion:** 2022-10
- **Final completion:** 2022-10
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02536183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02536183, "A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02536183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*